Rational use of crotalidae polyvalent immune Fab (ovine) in the management of crotaline bite

Annals of Emergency Medicine

Volumn 39, Issue 6, 2002, Pages 648-650

  Yip, Luke ^a  

^a ROCKY MOUNTAIN POISON AND DRUG CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYVALENT IMMUNE FAB; SNAKE VENOM ANTISERUM; UNCLASSIFIED DRUG;

ALGORITHM; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; EDITORIAL; ENVENOMATION; HUMAN; PRIORITY JOURNAL; SNAKEBITE;

EID: 0036271749     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2002.124450     Document Type: Article

References (21)

1. Initial postmarketing experience with Crotalidae polyvalent immune Fab for treatment of rattlesnake envenomation
2. Recurrence phenomena after immunoglobulin therapy for snake envenomations: Part 2. Guidelines for clinical management with crotaline Fab antivenom
3. Thrombolysis in Myocardial Infarction (TIMI) Trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase
4. Serial thrombolysis-related changes after thrombolytic therapy with TPA in patients with acute myocardial infarction
5. Lower-dose heparin with fibrinolysis is associated with lower rates of intracranial hemorrhage
6. Hemorrhagic complications of anticoagulant treatment
7. Major bleeding in outpatients treated with warfarin: Incidence and prediction by factors known at the start of outpatient therapy
8. Congenital afibrinogenemia and splenic rupture
9. Fibrinogen abnormalities
10. Congenital afibrinogenemia
11. Management of the hereditary coagulation disorders
12. Idiopathic thrombocytopenic purpura in children: Recognition and management
13. Idiopathic thrombocytopenic purpura: Beyond consensus
14. Initial management of immune thrombocytopenic purpura in children: Is supportive counseling without therapeutic intervention sufficient?
15. Idiopathic thrombocytopenia purpura: A practice guideline developed by explicit methods for the American Society of Hematology
16. The quantitative relation between platelet count and hemorrhage in patients with acute leukemia
17. Incidence of hemorrhagic complications in patients with cancer
18. Incidence of thrombocytopenia and serious hemorrhage in patients with solid tumors
19. Clinical risks of thrombolytic therapy
20. Affinity-purified, mixed monospecific crotalid antivenom ovine Fab for the treatment of crotalid venom poisoning
21. A randomized multicenter trial of crotaline polyvalent immune Fab (ovine) antivenom for the treatment of crotaline snakebite in the United States